

Supplementary Table 3. Systemic treatment after progression

| Variable | Chemotherapy holiday (n = 9) |
|----------------------------------|------------------------------|
| Subsequent chemotherapy regimens | |
| Total | 17 |
| 1 | 6 |
| 2 | 4 |
| ≥ 3 | 7 |
| Median | 3 |
| No. of total cycles | 89 |
| Type of chemotherapy regimens | |
| Capecitabine | 5 |
| Gemcitabine | |
| Eribulin | 4 |
| Vinorelbine | 1 |
| T-DM ₁ | 1 |
| Paclitaxel | |
| Docetaxel | 3 |
| Nab-paclitaxel | 1 |
| CMF | 2 |
| Subsequent endocrine regimens | |
| Total | 5 |
| 1 | 2 |
| 2 | 2 |
| ≥ 3 | 1 |
| Type of endocrine therapy | |
| Tamoxifen | |
| Letrozole | 2 |
| Exemestane | 1 |
| Exemestane + everolimus | 1 |
| Fulvestrant | 1 |

T-DM₁, trastuzumab emtansine; CMF, cyclophosphamide (oral) + methotrexate + 5-fluorouracil.